AstraZeneca plc (ADR) news

   Watch this stock
Showing stories 1 - 10 of about 156   

Articles published

AZN 27.78 -0.32 (-1.14%)
price chart
AbbVie Inc, AstraZeneca plc, and Others: What's Next?
AstraZeneca plc (ADR) (NYSE:AZN) has a very robust drug portfolio along with a very supportive drug pipeline consisting of multiple molecules, which are undergoing different phases of clinical trials.
Hot Stock to Track: AstraZeneca plc (ADR) (NYSE:AZN)
AstraZeneca plc (ADR) (NYSE:AZN) on April 29, 2016 reported first-quarter financial results met with a lukewarm reaction from investors on Friday morning, despite management having delivered a performance that was marginally better than consensus ...
AstraZeneca plc (ADR) Posts Q1 Earnings: Here's What to Expect  Bidness ETC
AstraZeneca plc (ADR) (AZN) Releases Earnings Results, Misses Expectations ...  Market Digest
AstraZeneca Plc (ADR) (NYSE:AZN) Latest Initiative To House 2 Million Genomes
AstraZeneca plc (ADR) (NYSE:AZN) has announced a new initiative to to house 2 million genome sequences aimed at gathering information that will facilitate the advancement of drug discovery and development.
AstraZeneca plc (ADR) (NYSE:AZN) Strikes Deal With ProStrakan Group For ...
AstraZeneca plc (ADR) (NYSE:AZN) disclosed that it reached a deal with ProStrakan Group for the rights to Moventig not only in the European Union but also Liechtenstein, Switzerland, Norway, and Iceland.
Will AstraZeneca plc (ADR) Trial Failure Impact Investors' Confidence?
AstraZeneca Plc (ADR) (NYSE:AZN) announced that its drug Brilinta (ticagrelor) did not achieve the primary endpoints in the patients suffering from the stroke.
Here's Why AstraZeneca Can Plunge Today  Bidness ETC
FDA Grants Orphan Status To AstraZeneca PLC (ADR) (NYSE:AZN) Neuromyelitis Drug
AstraZeneca plc (ADR) (NYSE:AZN) and its R&D arm, MedImmune, disclosed that its investigational anti-CD19 monoclonal antibody, MEDI-551, was given Orphan Drug Status by the FDA.
AstraZeneca Gains 1% Pre-Bell – Receives FDA Orphan Drug Status on Potential ...  Sonoran Weekly Review
Shares Of AstraZeneca PLC (ADR) (NYSE:AZN) Rated As Market Perform By Analysts ...
According to an update released by analysts at Leerink Swann the broker has now set a 'Market Perform' rating on shares of AstraZeneca PLC (ADR) (NYSE:AZN) with a price target of 34. Leerink Swann on Monday maintained AstraZeneca PLC (ADR)'s ...
Astrazeneca Plc (NYSE:AZN) Shorted Shares Decreased By 1.02%  Franklin Independent
AstraZeneca PLC (ADR) (NYSE:AZN) Receives 'Market Perform' Rating ...  Share Trading News
What Analysts Suggest About AstraZeneca plc (ADR) (NYSE:AZN)
AstraZeneca plc (ADR) (NYSE:AZN) received “Downgrade” rating by Goldman in a research note issued to investors on Apr-12-16 from Neutral to Sell.
AstraZeneca plc (ADR) (AZN) is Downgraded by Goldman to Sell  Market Digest
Will AstraZeneca plc and Eli Lilly Give Breakthrough in Alzheimer's?
AstraZeneca plc (ADR) (NYSE:AZN) and Eli Lilly and Co. (NYSE:LLY) has a breakthrough news regarding the treatment of Alzheimer's.
Downgrade of the Day: AstraZeneca plc (ADR)
AstraZeneca plc (ADR) (NYSE:AZN) received a stock rating downgrade from Goldman on Apr-12-16. In a note to investors, the firm issued a Sell rating.